

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-43. (canceled)

44. (new) A method of detecting in a test sample (i) one or more antibodies to human immunodeficiency virus (HIV) selected from the group consisting of antibody to HIV-1 envelope and antibody to HIV-2 envelope and (ii) one or more antigens selected from the group consisting of HIV-1 p24 core antigen and HIV-2 p26 core antigen, which method comprises:

(a) simultaneously contacting (i) at least one antigen selected from the group consisting of HIV-1 envelope antigen and HIV-2 envelope antigen, wherein the at least one antigen is bound to a solid phase, and (ii) at least one monoclonal antibody, or a fragment thereof, selected from the group consisting of 120A-270 produced by the cell line having American Type Culture Collection (ATCC) Deposit No. PTA-3890, 115B-151 produced by the cell line having ATCC Deposit No. PTA-2809, 117-289 produced by the cell line having ATCC Deposit No. PTA-2806, 103-350 produced by the cell line having ATCC Deposit No. PTA-2808, 115B-303 produced by the cell line having ATCC Deposit No. PTA-2810, and 108-394 produced by the cell line having ATCC Deposit No. PTA-2807, wherein the at least one monoclonal antibody, or fragment thereof, is covalently or non-covalently attached to a solid phase, with the test sample for an amount of time and under conditions sufficient to allow complexes between antibodies (or fragments thereof) and antigens to form,

(b) washing the solid phase of (i) and (ii) in (a), which was contacted with the test sample in (a), to remove uncomplexed antibodies and uncomplexed antigens,

(c) contacting the solid phase of (i) and (ii) in (a), which was washed in (b), with (i) at least one first conjugate, which comprises a signal-generating compound and an antigen selected from the group consisting of HIV-1 envelope antigen and HIV-2 envelope antigen, and (ii) at least one second conjugate, which comprises a signal-generating compound and a monoclonal antibody selected from the group consisting of anti-HIV-1 p24 core antigen antibody (or fragment thereof) and anti-HIV-2 p26 core

antigen antibody (or fragment thereof), for an amount of time and under conditions sufficient to allow (i') the at least one first conjugate to bind to an antibody, which was present in the test sample and is complexed with the at least one antigen that is bound to a solid phase, and (ii') the at least one second conjugate to bind to an antigen, which was present in the test sample and is complexed with the at least one monoclonal antibody, or fragment thereof, that is covalently or non-covalently attached to a solid phase,

(d) washing the solid phase of (i) and (ii) in (a), which was contacted with the at least one first conjugate and the at least one second conjugate in (c), to remove uncomplexed first conjugate and uncomplexed second conjugate, and

(e) detecting a signal,

whereupon the presence of (i) one or more antibodies to HIV selected from the group consisting of antibody to HIV-1 envelope and antibody to HIV-2 envelope and (ii) one or more antigens selected from the group consisting of HIV-1 p24 core antigen and HIV-2 p26 core antigen are detected.